entertainment -WSS

entertainment

author：Wikipedia 2025-10-01 04:12:35 - browse：288

Colorful broken DNA helix genome. -- health coverage from STAT — Adobe

In 2020, as biotech stocks surged amid the pandemic, a startup called Taysha Gene Therapies raised over $300 million off an audacious promise: It was going to license and develop gene therapies for at least 18 different rare and serious neurological diseases.

The effort brought hope for many rare disease families, some of whom had raised money to fund the UT-Southwestern scientist who designed the treatments after they saw no other options for their children.

Last week, the grand plan took perhaps a final blow. Taysha announced it would discontinue development of a treatment for giant axonal neuropathy, or GAN, a fatal, degenerative disease known to affect fewer than 100 people worldwide. The FDA, Taysha said, had requested an additional clinical trial that would be infeasible.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

WSS

Readout LOUD podcast: possible new ALS drug, artificial wombs

White House drug shortage group privately met with industry

White House drug shortage group privately met with industry

Biotech lab space demand falls sharply

How Vertex's cystic fibrosis drug is changing patients' lives

Microsoft strikes partnership with Duke Health to advance health AI

hotspot

entertainment

entertainment

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

FDA panel to weigh approval of NurOwn, controversial ALS drug

How to save PrEP access — and even expand it

2 US Navy sailors arrested for allegedly spying for China

How to save PrEP access — and even expand it

The drug industry sees a key ally in the Senate prevail

Hepatitis C has a cure — but many Americans still lack access to it

Drug for rare kidney disease narrowly misses mark in clinical trial

George Santos makes 1st court appearance after pleading not guilty to 13 counts

CDC's new outbreak response network to include Northeastern

explore

CommonSpirit Health keeps growing, even as it loses money

What Mike Pence has said that could be used in a Donald Trump trial

OTC birth control: A brief history of over the counter pill design

Intarcia’s device

Biotech stock slump in 2023: awaiting the turnaround

Experts study whether long Covid risk adds up with each reinfection

explore

entertainment

leisure time

knowledge